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Population prevalence of persons infected with SARS-CoV-2, 
the virus that causes coronavirus disease 2019 (COVID-19), 
varies by subpopulation and locality. U.S. studies of 
SARS-CoV-2 infection have examined infections in nonran-
dom samples (1) or seroprevalence in specific populations* 
(2), which are limited in their generalizability and cannot be 
used to accurately calculate infection-fatality rates. During 
April 25–29, 2020, Indiana conducted statewide random 
sample testing of persons aged ≥12 years to assess prevalence 
of active infection and presence of antibodies to SARS-CoV-2; 
additional nonrandom sampling was conducted in racial and 
ethnic minority communities to better understand the impact 
of the virus in certain racial and ethnic minority populations. 
Estimates were adjusted for nonresponse to reflect state demo-
graphics using an iterative proportional fitting method. Among 
3,658 noninstitutionalized participants in the random sample 
survey, the estimated statewide point prevalence of active 
SARS-CoV-2 infection confirmed by reverse transcription–
polymerase chain reaction (RT-PCR) testing was 1.74% (95% 
confidence interval [CI] = 1.10–2.54); 44.2% of these persons 
reported no symptoms during the 2 weeks before testing. 
The prevalence of immunoglobulin G (IgG) seropositivity, 
indicating past infection, was 1.09% (95% CI = 0.76–1.45). 
The overall prevalence of current and previous infections of 
SARS-CoV-2 in Indiana was 2.79% (95% CI = 2.02–3.70). In 
the random sample, higher overall prevalences were observed 
among Hispanics and those who reported having a household 
contact who had previously been told by a health care provider 
that they had COVID-19. By late April, an estimated 187,802 
Indiana residents were currently or previously infected with 
SARS-CoV-2 (9.6 times higher than the number of confirmed 
cases [17,792]) (3), and 1,099 residents died (infection-fatality 
ratio = 0.58%). The number of reported cases represents only a 
fraction of the estimated total number of infections. Given the 
large number of persons who remain susceptible in Indiana, 
adherence to evidence-based public health mitigation and 
containment measures (e.g., social distancing, consistent and 
correct use of face coverings, and hand hygiene) is needed to 
* https://www.medrxiv.org/content/10.1101/2020.04.14.20062463v2.
reduce surge in hospitalizations and prevent morbidity and 
mortality from COVID-19.
The study population was randomly selected from a list of 
Indiana residents derived from tax returns, including filers and 
dependents. State databases were cross-checked for recent con-
tact information, and institutionalized and deceased persons 
were removed. Stratified random sampling was conducted 
among all persons aged ≥12 years using Indiana’s 10 public 
health preparedness districts as sampling strata. After the study 
was announced, 15,495 participants were contacted by the 
state health department via postcard, text message, e-mail, 
or telephone, depending on available contact information. 
The number of participants were determined by assuming 
prevalences ranging from 0.5% to 15% and a margin of error 
of 1 percentage point. Consenting participants were able to 
select a testing time, by phone or online, at one of 68 state-
wide sites and complete a research intake form that included 
questions about their reasons for participating, demographic 
characteristics (e.g., age, sex, race, and ethnicity), number of 
children aged <18 years living in the household, highest level 
of education achieved, general health status, use of tobacco or 
vaping products, COVID-19–compatible symptoms† during 
the past 2 weeks (asked at time of registration and prompted 
to update if they experienced any new symptoms at testing 
site check-in), and whether the participant or any household 
member had received a provider diagnosis of COVID-19. 
The study was deemed a public health surveillance activity by 
the Indiana University Institutional Review Board and was 
exempted from human subjects review.
Logistical support at testing locations was coordinated by the 
state health department with support from other state agencies, 
the Indiana National Guard, and private organizations. During 
April 25–29, personnel used swabs to collect nasopharyngeal speci-
mens for RT-PCR testing to detect the presence of SARS-CoV-2 
and 2–3 mL samples of blood by venipuncture for antibody testing 
using a chemiluminescent microparticle immunoassay for detec-
tion of SARS-CoV-2 IgG. Participants could access results and 
explanations of their test results online within 3 days of testing 
and were linked to additional resources as needed.
† Fever, cough, shortness of breath, chest pain, muscle aches, chills, tiredness or 
fatigue, sore throat, runny nose, headache, diarrhea, vomiting, loss of sense of 
smell, and loss of sense of taste.
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Because racial and ethnic minority populations responded at 
lower rates in the sample (Table 1), civic leaders were enlisted 
to establish 2 days of nonrandom testing (May 2–3) hosted 
at Indianapolis locations in two racial/ethnic minority popu-
lations. Doing so was motivated by the need to understand 
the impact of the virus in populations that have been dispro-
portionately affected by the COVID-19 pandemic and been 
shown to have higher proportions of essential workers, who 
might therefore continue to be at elevated risk for infection (4). 
An additional motivation was to compare results of random 
and nonrandom samples as a way to inform the limitations of 
nonrandom sampling occurring in the United States. Clergy 
and community leaders helped mobilize community members 
by increasing trust and engagement with the testing program. 
Because some participants in the nonrandom testing group 
might have chosen to participate because of concerns that they 
might be infected, possibly resulting in selection bias; findings 
from the nonrandom testing are reported separately.
Population prevalence estimates were calculated for persons 
who were currently or previously infected with SARS-CoV-2. 
Persons with positive results for both tests (16 in random sample 
and 100 in nonrandom sample) were classified as currently 
infected. Persons were classified as asymptomatic if they indicated 
that they had no symptoms on the checklist during the 2 weeks 
before testing. To adjust for nonresponse, data were weighted for 
age, race (dichotomized as white or nonwhite), and Hispanic 
ethnicity. Data for each person who received testing were then 
reweighted according to the proportions of these three factors 
in each of the 10 sampling strata, as determined by U.S. Census 
population estimates. Sampling was performed using R software 
(version 4.0.0; The R Foundation). Analyses were performed using 
SAS (version 9.4; SAS Institute), and bootstrapping methods were 
used to obtain point estimates, p-values, and CIs.
The nonrandom sample was analyzed separately. To account for 
clustering effects resulting from members of the same household 
being tested, which did not apply to the random sample, estimates 
were obtained using generalized estimating equations assuming 
a binomial distribution for the presence of current infection and 
antibodies. Analyses were performed using R software.
Among 15,495 randomly selected persons, 3,658 (23.6%) 
participated, 3,629 (99.2%) of whom had at least one test 
result available (Table 1). Overall, approximately 55% of 
participants were female, 92% were white, and 98% were 
non-Hispanic. Approximately one third each were aged 
<40 years, 40–59 years, and ≥60 years. Statewide, 1.74% of 
persons (unweighted n = 47) had a positive RT-PCR test result 
(95% CI = 1.10%–2.54%), and 1.01% (95% CI = 0.76%–
1.45%) (unweighted n = 38) had samples that were seroposi-
tive, resulting in an estimated overall population SARS-CoV-2 
prevalence of active or current infection in Indiana of 2.79% 
(95% CI = 2.02%–3.70%). The overall prevalence was sig-
nificantly higher among Hispanics (8.3%) than among non-
Hispanics (2.3%) (p = 0.03). Participants who reported having 
a current household member who had previously been told 
by a provider that they had COVID-19 had a higher overall 
prevalence (33.6% versus 2.2%; p = 0.004).
Among all participants with positive RT-PCR results, 44.2% 
reported no symptoms during the 2 weeks before testing. 
Among these persons, no differences by demographic charac-
teristics were identified. However, a higher but nonsignificant 
percentage of males reported being asymptomatic (60.3%) 
than did females (24.5%; p = 0.056) at the time of testing.
The nonrandom sample group included 898 persons 
(Table 2). In this more racially and ethnically diverse group, 
22.8% of participants had a positive RT-PCR test result, 
indicating active infection, and an additional 5.8% were sero-
positive. Among those with active infection, 20.2% reported 
being asymptomatic.
Discussion
The results of this large statewide population prevalence 
study, in a state with a population of 6.73 million,§ indicate 
that an estimated 187,802 Indiana residents were infected with 
SARS-CoV-2 from the start of the pandemic through April 29, 
2020, a population prevalence of 2.8%. The finding that more 
persons had samples that tested positive for SARS-CoV-2 by 
RT-PCR, indicating an active infection, than for SARS-CoV-2 
antibodies suggests that Indiana was in the early stage of the 
pandemic when the study was conducted. In late April, a total 
of 17,792 COVID-19 cases had been confirmed using con-
ventional testing strategies (3), and were reported in the state, 
including 1,099 COVID-19–associated deaths. Based on the 
estimated total number of infections, the estimated infection-
fatality rate was 0.58%, or approximately six times the 0.1% 
mortality rate for influenza (5). This fatality rate is lower than 
the infection-fatality rate of 1.3 observed on a cruise ship (2) 
but consistent with an extrapolated infection-fatality rate in 
China of 0.66% derived from a nonrandom sample of persons 
repatriated to their countries from China after the outbreak (6).
Because of the higher prevalence and smaller percentage 
of asymptomatic persons in the nonrandom sample, those 
estimates (and estimates from nonrandom samples from other 
states) might be subject to selection bias and are therefore not 
as representative as are estimates from random samples. The 
Indiana estimates of seroprevalence might be more comparable 
with the seroprevalence from a county-based random sample 
study in Los Angeles, California, that reported a seroprevalence 
§ https://www.census.gov/quickfacts/IN.
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TABLE 1. Estimated point prevalence* of current or past infection with SARS-CoV-2, by demographic characteristics and urbanicity — Indiana, 
April 25–29, 2020
Characteristic  
(no. with information)
Random  
sample size,  
no. (%)
Expected  
sample size,†  
no.
SARS-CoV-2 positive by 
RT–PCR for current 
infection (N = 3,605)
Asymptomatic  
(among RT-PCR  
positive results)
SARS-CoV-2 positive by 
IgG for past infection§  
(N = 3,518)
Total population 
prevalence¶ (valid test 
result: N = 3,632)
% (95% CI) % % (95% CI) % (95% CI)
Totals 3,658 N/A 1.74 (1.1–2.5) 44.2 1.09 (0.8–1.5) 2.79 (2.0–3.7)
Sex (3,651)
Female 1,995 (55) 1,850 1.42 (0.8–2.2) 24.7 1.02 (0.5–1.6) 2.41 (1.6–3.3)
Male 1,656 (45) 1,801 2.13 (0.9–3.9) 60.2 1.18 (0.7–1.9) 3.26 (1.9–5.0)
Race (3,658)
White 3,373 (92) 3,180 1.47 (1.0–2.1) 40.3 1.02 (0.6–1.5) 2.70 (1.7–3.3)
Nonwhite 281 (8) 479 3.39 (0.6–7.9) 54.8 1.54 (0.4–3.1) 4.83 (1.7–9.5)
Hispanic origin (3,658)
Hispanic 80 (2) 259 6.85 (1.2–15.2) 56.9 1.49 (0.3–4.9) 8.32 (2.7–15.8)**
Non-Hispanic 3,578 (98) 3,399 1.28 (0.9–1.7) 38.1 1.06 (0.7–1.5) 2.29 (1.9–2.7)**
Urbanicity (3,658)††
Urban†† 2,323 (63) 2,303 1.72 (0.8–3.0) 47.3 1.04 (0.6–1.5) 2.72 (1.6–4.0)
Rural/Mixed 910 (25) 874 2.05 (1.0–3.2) 34.6 1.24 (0.5–2.1) 3.23 (2.1–4.8)
Rural 425 (12) 480 1.20 (0.3–2.3) 54.5 1.08 (0.3–2.5) 2.25 (0.8–4.0)
Age group (yrs) (3,658)
<40 1,017 (28) 1,928 1.71 (0.9–2.7) 34.5 1.39 (0.7–2.2) 3.05 (1.9–4.3)
40–59 1,328 (36) 922 2.09 (1.0–3.5) 47.8 1.08 (0.5–1.8) 3.14 (1.9–5.0)
≥60 1,313 (36) 808 0.92 (0.4–1.5) 45.4 0.77 (0.3–1.3) 1.65 (1.0–2.4)
Ever told by a doctor respondent had positive test result for SARS-CoV-2 (3,658)
Yes 53 N/A 24.4 (2.7–49.0)** N/A 16.8 (4.0–34.5)** 40.9 (15.4–63.8)**
No 3,605 N/A 1.3 (1.0–2.0)** N/A 0.8 (0.6–1.2)** 2.2 (1.6–3.0)**
Ever told by a doctor that household member had positive test result for SARS-CoV-2 (3,629)
Yes 50 N/A 29.4 (3.8–53.1)** N/A 6.0 (0.9–14.0) 33.6 (10.9–59.0)**
No 3,608 N/A 1.3 (0.8–1.8)** N/A 1.0 (0.7–1.4) 2.2 (1.7–2.9)**
Abbreviations: CI = confidence interval; IgG = immunoglobulin G; N/A = not applicable; RT-PCR = reverse transcription–polymerase chain reaction.
 * Point estimates and CIs were produced by bootstrap methods.
 † Based on U.S. Census population estimates.
 § Based on presence of antibodies without evidence of current infection.
 ¶ Evidence of current or previous infection.
 ** p<0.05 based on a resampling test using bootstrap methods.
 †† Purdue Rural Indiana Classification System (https://pcrd.purdue.edu/ruralindianastats/geographic-classifications.php#table1).
of 4.7% in mid-April 2020 (2), which is higher than this 
statewide seropositivity rate.
Participants with a household member who had received 
a diagnosis of COVID-19 were 15 times more likely to have 
had positive test results for SARS CoV-2 than were those who 
did not. This, along with the relatively low observed statewide 
prevalence, suggests that social distancing efforts (e.g., stay-
at-home orders) that were in effect during March 24–May 3, 
2020, likely minimized community spread. Because these 
policies have been shown to be effective (7), in the absence of 
a vaccine, they constitute important approaches for prevention 
of transmission. These findings also underscore the importance 
of assuring effective protection of household members when 
patients with COVID-19 undergo home isolation.
Racial minorities in the nonrandom sample and Hispanics 
in the random sample experienced higher prevalences than 
did whites and non-Hispanics, suggesting the need for com-
munication strategies tailored to the culture and languages of 
local communities, as well as more testing and contact trac-
ing resources to prevent additional infections in these groups. 
Such initiatives should involve local community leaders who 
can help mobilize persons to participate despite a potential 
mistrust of government within these communities (8). The 
significantly higher observed prevalence in minority commu-
nities might have been due in part to social conditions that 
increased transmission opportunities, including minorities 
being disproportionately represented among essential workers.
The findings in this report are subject to at least five 
limitations. First, the main sample was randomly selected but 
achieved a low response rate of 23.6%, although standard 
practices were followed to adjust for nonresponse. However, 
respondents might have been subject to response bias, which 
could have resulted in underestimates or overestimates. Second, 
limitations in the tests themselves or the testing procedures 
might have caused inaccurate results. Whereas the laboratory-
based negative percent agreement was 100% for all tests, the 
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TABLE 2. Estimated point prevalence of current or past infection with SARS-CoV-2, by demographic characteristics — nonrandom sample, 
Indiana, May 2–3, 2020
Characteristic*
Total nonrandom 
sample 
 size, no. (%)
%
p value¶
SARS-CoV-2 positive 
by RT-PCR for 
current infection  
(N = 898)
Asymptomatic 
(among RT-PCR 
positive results)
SARS-CoV-2 positive 
by IgG for past 
infection†  
(N = 889)
Total population 
prevalence§ (valid 
test result: N = 898)
Total 898 22.8 20.2 5.8 28.6 —
Sex
Female 523 (58.2) 21.7 22.6 6.0 27.7 0.369
Male 375 (41.8) 24.2 17.4 5.5 29.7
Race
White 208 (23.1) 19.5 24.6 4.7 24.2 <0.001
Black 295 (32.9) 9.0 35.6 6.8 15.8
Other (including multiracial) 395 (44.0) 36.9 14.4 5.7 42.5
Hispanic origin
Hispanic 396 (44.1) 37.6 17.6 7.0 44.7 <0.001
Non-Hispanic 502 (55.9) 13.0 20.7 4.9 17.9
Age group (yrs)
<20 77 (8.6) 31.0 30.0 7.5 38.5 <0.001
20–39 277 (30.8) 29.3 13.0 6.5 35.8
40–59 369 (41.1) 24.9 20.5 5.2 30.1
60–79 169 (18.8) 6.9 37.7 5.0 11.9
≥80 6 (0.7) 0 0 16.8 16.8
Ever told by a doctor respondent had positive test result for SARS-CoV-2
Yes 55 (6.1) 39.2 13.8 14.1 53.3 0.002
No 843 (93.9) 21.6 20.8 5.2 26.9
Ever told by a doctor that household member had positive test result for SARS-CoV-2
Yes 97 (10.8) 46.1 16.1 11.0 57.1 <0.001
No 801 (89.2) 20.2 20.8 5.2 25.4
Abbreviations: IgG = immunoglobulin G; RT-PCR = reverse transcription–polymerase chain reaction.
* Data are adjusted for clustering within home address.
† Determined by presence of antibodies without evidence of current infection.
§ Evidence of current or previous infection.
¶ P-values compare group differences for overall population prevalence.
positive percent agreement¶ was 90% for one RT-PCR test 
and 100% for the others. Samples from participants tested 
in the early stages of infection or poor sampling technique 
could have caused false-negative results. The antibody test 
has an estimated 100% sensitivity 14 days after symptom 
onset in SARS-CoV-2–infected persons and a specificity of 
99.6%, which could have caused some false-positive results. 
Third, in the nonrandom sample, self-selection by potentially 
more symptomatic persons might have contributed to the 
higher overall prevalence of current and previous infections 
and lower prevalence of asymptomatic infections. Population-
based prevalence estimates from nonrandom samples should 
be interpreted with caution; however, focused nonrandom 
sampling among groups at higher risk for infection can provide 
data to enhance public health mitigation and containment 
strategies. Fourth, the study was conducted in Indiana at one 
point in time and therefore is not generalizable to other states 
and times. Finally, the study excludes persons who did not 
file state tax returns, those who were institutionalized, and 
children aged <12 years. 
This study does, however, provide context for the impor-
tance of random sample studies in statewide populations. 
Policymakers need to have generalizable population estimates 
of SARS-CoV-2 prevalence to establish baseline prevalence 
rates and to understand the groups most at risk for infection. 
The uninfected majority of state residents represents the 
minimum number of persons who are susceptible to the virus 
because it remains to be determined whether those previously 
infected are susceptible to reinfection. Given the large num-
ber of persons who remain susceptible in Indiana, adherence 
to evidence-based public health mitigation and containment 
measures (e.g., social distancing, consistent and correct use of 
face coverings, and hand hygiene) continues to be needed to 
reduce surge in hospitalizations and prevent morbidity and 
mortality from COVID-19.
¶ Statistical guidance on reporting results from studies evaluating diagnostic tests 
states that when a new test is evaluated by a comparison with a nonreference 
standard, unbiased estimates of sensitivity and specificity cannot be calculated. The 
estimates are called positive percent agreement and negative percent agreement, 
reflecting that the estimates are not of accuracy but of agreement of the new test 
with the nonreference standard. (https://www.fda.gov/media/71147/download).
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Summary
What is already known about this topic?
No state has conducted a random sample study to determine 
the population prevalence of SARS-CoV-2 infection at a given 
point in time.
What is added by this report?
In a random sample of Indiana residents aged ≥12 years, the 
estimated prevalence of current or previous SARS-CoV-2 
infection in late April 2020 was 2.79%. Among persons with 
active infection, 44% reported no symptoms.
What are the implications for public health practice?
The number of reported cases represents an estimated one of 
10 infections. Given that many persons in Indiana remain 
susceptible, adherence to evidence-based public health 
mitigation measures (e.g., social distancing, consistent and 
correct use of face coverings, and hand hygiene) is needed to 
reduce surge in hospitalizations and prevent morbidity and 
mortality from COVID-19.
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